Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM92 CAR-T in Advanced Gastric or Pancreatic Adenocarcinoma
NCT05275062Phase 1Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Mar 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IM92 in gastric adenocarcinoma, pancreatic adenocarcinoma (PDAC) and esophagogastric junction adenocarcinoma (GEJA), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Incidence of adverse events at 28 days. Status: unknown.
02
Drugs
IM92
03
Conditions
gastric adenocarcinomapancreatic adenocarcinoma (PDAC)esophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT05275062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275062.